================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported): May 7, 2008


                               TRANSGENOMIC, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


       Delaware                     000-30975                  911789357
- ------------------------      ------------------------   -----------------------
(State of Incorporation)      (Commission File Number)       (IRS Employer
                                                          Identification Number)


        12325 Emmet Street, Omaha, Nebraska                       68164
- ------------------------------------------------------   -----------------------
      (Address of principal executive offices)                 (Zip Code)


                                 (402) 452-5400
              ----------------------------------------------------
              (Registrant's telephone number, including area code)


                                 Not applicable
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))

================================================================================



Item 2.02 Results of Operations and Financial Condition

      On May 7, 2008,  Transgenomic,  Inc. issued a press release announcing its
financial  results for the first  quarter  2008. A copy of the press  release is
being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

      The  information  referenced in this Current Report on Form 8-K (including
Exhibit 99 referenced in Item 9.01 below) is being `furnished" under "Item 2.02.
Results of Operations and Financial Condition" and, as such, shall not be deemed
to be "filed" for the purposes of Section 18 of the  Securities  Exchange Act of
1934, as amended (the "Exchange  Act"), or otherwise  subject to the liabilities
of that Section.  The  information  set forth in this Current Report on Form 8-K
(including  Exhibit 99 referenced in Item 9.01 below) shall not be  incorporated
by reference into any registration  statement or other document  pursuant to the
Securities Act of 1933, as amended (the  "Securities  Act"),  except as shall be
expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(c)   Exhibits.

      (99)  Press release  dated May 7, 2008,  announcing  Transgenomic,  Inc.'s
            financial results for the first quarter 2008.


                                   SIGNATURES

      Pursuant to the  requirements  of the Securities  Exchange Act of 1934, as
amended,  the  registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.


Dated:  May 7, 2008                     TRANSGENOMIC, INC.


                                        By: /s/ Debra A. Schneider
                                            ------------------------------------
                                            Debra A. Schneider
                                            Chief Financial Officer


                                       2